Kodein Orifarm Healthcare

Codeine phosphate sesquihydrate, the active ingredient in Kodein Orifarm Healthcare, is an opioid analgesic presented as an oral formulation for systemic use. Originating from the European Union market, the product conforms to EU pharmaceutical standards and is employed to relieve mild to moderate pain and to suppress coughing in appropriate patients.

GNH USA supplies Kodein Orifarm Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring batch consistency and rigorous quality control throughout manufacturing.

Codeine phosphate sesquihydrate acts on the central opioid pathway to provide analgesia and antitussive effects.

- Mild to moderate acute pain: provides analgesia by activating central mu‑opioid receptors. - Chronic non‑cancer pain: may be incorporated into a multimodal pain‑management regimen. - Cough associated with upper respiratory infections: suppresses the cough reflex through central mechanisms.

Codeine phosphate sesquihydrate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: feeling of stomach upset or urge to vomit. - Constipation: reduced bowel movements and hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Dizziness: sensation of light‑headedness or imbalance. - Dry mouth: reduced salivation leading to a parched feeling. - Vomiting: expulsion of stomach contents.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Dependence or addiction: compulsive use despite harmful consequences. - Hypotension: unusually low blood pressure causing faintness. - Seizures: rare occurrence of convulsive episodes.

When prescribing or dispensing codeine phosphate sesquihydrate, several safety considerations should be observed.

- Assess pain severity and cough etiology: ensure the indication aligns with approved uses. - Avoid in patients with significant respiratory depression: risk of worsening ventilation. - Use caution in the elderly: increased susceptibility to sedation and falls. - Monitor for signs of dependence or misuse: educate patients on proper use. - Avoid concomitant CNS depressants when possible: may potentiate sedation. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Codeine phosphate sesquihydrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other opioids: additive respiratory depression. - Benzodiazepines or barbiturates: heightened CNS depression. - Alcohol: increased sedation and respiratory risk.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): reduced conversion to active metabolites. - Antihistamines: may enhance drowsiness. - SSRIs or SNRIs: potential for serotonin syndrome when combined with high opioid doses.